--- title: "NP47926 Biologic, Biosimilar's and Methotrexate Injections" ocid: "ocds-h6vhtk-077614" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-077614" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-077614.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-077614.json" source: "Find A Tender Service" current_stage: "Tender" buyer: "The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)" published: "2026-09-21" --- # NP47926 Biologic, Biosimilar's and Methotrexate Injections Buyer: The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) Current stage: Tender OCID: ocds-h6vhtk-077614 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-077614) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-077614.json) ## Summary Public Services Delivery Scotland, acting for NHS Scotland, is procuring pharmaceutical products for NHS Scotland bodies and Integrated Joint Boards across Scotland. The requirement covers biologic and biosimilar medicines, plus methotrexate injections, including adalimumab, etanercept, golimumab, infliximab for intravenous infusion and subcutaneous injection, omalizumab, tocilizumab, ustekinumab and tildrakizumab. Methotrexate products include pre-filled self-injection devices and syringes at 25mg/1ml and 50mg/1ml concentrations. This is a goods contract for the supply of medicines, classified under CPV 33600000 for pharmaceutical products. The procurement is arranged as a framework, with individual product lines split into lots. Some lots are intended for one supplier, while others allow multiple framework participants, subject to the stated limits. The process reached tender: the buyer invited offers through an open procedure, with electronic submission in English. The tender deadline is 21 October 2026 at 12:00 UK time; bids are opened and the award period begins at that time. The framework contract period is 720 days, with an option to extend by any number of periods up to a further 24 months, subject to at least three months’ written notice. The estimated overall value is £334,866,015. Lot values include £68,840,541 for adalimumab, £56,785,379 for etanercept, £68,865,598 for ustekinumab and £30,991,783 for infliximab intravenous infusion. Evaluation is based on price at 95% and API sources at 5%. Variants are not allowed, and the framework can have up to 18 participants. This opportunity suits pharmaceutical manufacturers, marketing authorisation holders, wholesalers and specialist medicines suppliers able to supply the specified biologic, biosimilar and methotrexate products to NHS Scotland. Bidders must hold a valid, current UK Marketing Authorisation approved by the MHRA for every medicine tendered, using a PL, PLGB or PLPI number. Suppliers and subcontractors must hold BS EN ISO 9001 certification or an equivalent standard. Products must comply with MHRA best-practice guidance on labelling and packaging, with samples supplied on request. Bidders must provide a climate change plan covering actions to reduce emissions. The successful framework participants must support community benefits, demonstrate relevant benefits delivered in Scotland and propose further benefits or engage with the NHS Scotland Community Benefits Gateway. Subcontracting is permitted under a contract clause. ## Notice Supply of Biologics, Biosimilars and Methotrexate Injections to NHS Scotland. ### Lot Information Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Device Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Infliximab Subcutaneous Injection Supply of infliximab subcutaneous injection to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (50mg/1ml concentration) Pre-Filled Syringe Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Adalimumab Supply of adalimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 7 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Etanercept Supply of etanercept to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Golimumab Supply of golimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Infliximab Intravenous Infusion Supply of infliximab intravenous infusion to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 6 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Omalizumab Supply of omalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Tocilizumab Supply of tocilizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Ustekinumab Supply of ustekinumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 9 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Tildrakizumab Supply of tildrakizumab to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/088983-2026 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Tender | ## Dates | Field | Value | | --- | --- | | Publication date | 21 Sep 2026 | | Submission deadline | 21 Oct 2026 | | Future notice date | Not specified | | Award date | Not specified | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £334,866,015 | | Lots value | £334,866,016 | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Active | | Lots status | Active | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) | | Locality | EDINBURGH | | Postcode area | Edinburgh | | Postcode | EH12 9EB | | Country | Scotland | | ITL 1 | TLM Scotland | | ITL 2 | TLM1 East Central Scotland | | ITL 3 | TLM13 City of Edinburgh | | Local authority | City of Edinburgh | | Electoral ward | Drum Brae/Gyle | | Westminster constituency | Edinburgh South West | | Delivery location | TLM Scotland | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products - 33650000 - General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 33652000 - Antineoplastic and immunomodulating agents - 33690000 - Various medicinal products ## Release History - 21 Sep 2026 at 10:11 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/088983-2026 ## Notice URLs - http://publicservicesdelivery.scot/about/procurement/ - http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 - http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 - https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000841676 - https://scotcourts.gov.uk/the-courts/sheriff-court/about-sheriff-courts - https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/ - https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/ - https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883 - https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-077614. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-077614.json.